Alvotech
Better Access. Better Lives.
We are led by science, driven by passion, and committed to biosimilars. We are continually evaluating additional pipeline opportunities to bring a strategic and robust selection of treatment options to patients around the world.
AVT02
- Biosimilar candidate
- High-concentration, low-volume adalimumab
- Reference biologic
- HUMIRA®
- Therapeutic area
- Immunology
Approved by
- EU/EEA
- Canada
- UK
- Egypt
- Saudi Arabia
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT04
- Biosimilar candidate
- ustekinumab
- Reference biologic
- STELARA®
- Therapeutic area
- Immunology
Approved by
- Japan
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT23*
- Biosimilar candidate
- omalizumab
- Reference biologic
- XOLAIR®
- Therapeutic area
- Respiratory
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT03
- Biosimilar candidate
- denosumab
- Reference biologic
- PROLIA®/XGEVA®
- Therapeutic area
- Bone Disease
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT05
- Biosimilar candidate
- golimumab
- Reference biologic
- SIMPONI®/SIMPONI ARIA®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT06
- Biosimilar candidate
- aflibercept
- Reference biologic
- EYLEA®
- Therapeutic area
- Ophthalmology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT16
- Biosimilar candidate
- vedolizumab
- Reference biologic
- ENTYVIO®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT33
- Biosimilar candidate
- pembrolizumab
- Reference biologic
- KEYTRUDA®
- Therapeutic area
- Oncology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT19
- Biosimilar candidate
- Undisclosed
- Reference biologic
- Undisclosed
- Therapeutic area
- Undisclosed
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT28
- Biosimilar candidate
- Undisclosed
- Reference biologic
- Undisclosed
- Therapeutic area
- Undisclosed
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT41
- Biosimilar candidate
- Undisclosed
- Reference biologic
- Undisclosed
- Therapeutic area
- Undisclosed
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
HUMIRA is a registered trademark of AbbVie Inc.
STELARA, SIMPONI and SIMPONI ARIA are registered trademarks of Johnson & Johnson Inc.
XOLAIR is a registered trademark of Novartis AG.
PROLIA and XGEVA are registered trademarks of Amgen Inc.
EYLEA is a registered trademark of Regeneron Pharmaceuticals Inc.
ENTYVIO is a registered trademark of Millenium Pharmaceuticals Inc.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp.